Motixafortide: Research & Studies

Research Overview#

Motixafortide has a strong evidence base centered on the Phase 3 GENESIS trial, which provided the data supporting FDA approval. The trial demonstrated clear superiority over G-CSF alone for stem cell mobilization, with results published in Nature Medicine.

Phase 3 GENESIS Trial (PMID 37069359)#

The GENESIS trial was the pivotal registration study for motixafortide.

Study Design#

• Design: Prospective, Phase 3, double-blind, placebo-controlled, multicenter
• Enrollment: 122 adult patients with multiple myeloma undergoing ASCT (Part 2)
• Randomization: 2:1 (motixafortide + G-CSF vs. placebo + G-CSF)
• Sites: 18 sites across 5 countries
• Primary endpoint: Proportion collecting 6 million or more CD34+ cells/kg in 2 apheresis sessions
• Secondary endpoint: Proportion achieving target in 1 apheresis session

Key Results#

Stem Cell Quality#

Beyond quantity, motixafortide preferentially mobilized immunophenotypically and transcriptionally primitive HSCs, which may translate to improved engraftment kinetics and long-term hematopoietic reconstitution.

Engraftment Outcomes#

Patients transplanted with motixafortide-mobilized grafts showed successful engraftment with neutrophil and platelet recovery timelines consistent with or better than historical controls.

Additional Clinical Studies#

Allogeneic Stem Cell Mobilization#

A Phase 1/2 study evaluated motixafortide for HSC mobilization from healthy donors for allogeneic transplantation, showing effective mobilization of CD34+ cells.

Sickle Cell Disease Gene Therapy#

A first-in-human proof-of-concept study is evaluating motixafortide alone and in combination with natalizumab for HSC mobilization in sickle cell disease patients undergoing gene therapy.

Oncology Applications#

Motixafortide has been investigated in combination with pembrolizumab and chemotherapy for pancreatic cancer, leveraging the role of CXCR4/CXCL12 in tumor immune evasion.

Evidence Quality Assessment#

Research Evidence Context#

Motixafortide belongs to the Immune category of research peptides. The research evidence for Motixafortide spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Motixafortide:

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial#

Authors: Crees ZD, Rettig MP, Jayasinghe RG, et al. (2023) — Nature Medicine

Phase 3 GENESIS trial evaluating motixafortide plus G-CSF versus placebo plus G-CSF for hematopoietic stem cell mobilization in 122 multiple myeloma patients across 18 sites in five countries.

Key Findings:

• 92.5% of motixafortide group collected 6 million or more CD34+ cells/kg in 2 apheresis sessions versus 26.2% placebo (OR 53.3, p<0.0001)
• 88.8% achieved target collection in one session versus 9.5% placebo (OR 118.0, p<0.0001)
• Motixafortide preferentially mobilized primitive hematopoietic stem cells
• Well tolerated with injection site reactions as the most common adverse event

Limitations: Open-label Part 1 dose selection with 12 patients. Blinded Part 2 enrolled 122 patients. Post-ASCT engraftment and outcomes were secondary assessments. Long-term transplant outcomes data are limited.

Evidence Quality Assessment#

The overall evidence level for Motixafortide is classified as high, supported by large, well-designed clinical trials with robust methodology.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Motixafortide have been identified:

• Long-term transplant outcomes and disease-free survival compared to plerixafor-mobilized grafts
• Head-to-head comparison with plerixafor (Mozobil)
• Efficacy in difficult-to-mobilize patients (heavily pretreated, prior lenalidomide)
• Optimal use in combination with plerixafor for rescue mobilization
• HSC mobilization for allogeneic transplantation (Phase 1/2 data available)
• Gene therapy applications (sickle cell disease HSC mobilization)
• Anti-tumor efficacy in pancreatic cancer and AML (Orphan Drug programs)

Addressing these research gaps will be important for establishing a more complete understanding of Motixafortide's therapeutic potential and safety profile.

Related Reading#

• Motixafortide overview and research guide
• Motixafortide dosing protocols
• Motixafortide molecular structure